



Artisan Global Discovery Fund

QUARTERLY
Commentary

Artisan Partners Global Funds plc

As of 31 December 2023

For Institutional Investors – Not for Onward Distribution

Investment Process

We seek to invest in companies that possess franchise characteristics, are benefiting from an accelerating profit cycle and are trading at a discount to our estimate of private market value. Our investment process focuses on two distinct elements—security selection and capital allocation. We overlay our investment process with broad knowledge of the global economy.

Security Selection

We seek to identify companies that have franchise characteristics (e.g., low-cost production capability, possession of a proprietary asset, dominant market share or a defensible brand name), are benefiting from an accelerating profit cycle and are trading at a discount to our estimate of private market value. We also assess key environmental, social and governance (ESG) issues that could impact future stock returns. We look for companies that are well positioned for long-term growth, which is driven by demand for their products and services, at an early enough stage in their profit cycle to benefit from the increased cash flows produced by the emerging profit cycle.

Capital Allocation

Based on our fundamental analysis of a company's profit cycle, we divide the portfolio into three parts. GardenSM investments are small positions in the early part of their profit cycle that may warrant more sizeable allocations as their profit cycle accelerates. CropSM investments are positions that are being increased to a full weight because they are moving through the strongest part of their profit cycles. HarvestSM investments are positions that are being reduced as they near our estimates of full valuation or their profit cycles begin to decelerate.

Broad Knowledge

We overlay the security selection and capital allocation elements of our investment process with a desire to invest opportunistically across the entire global economy. We seek broad knowledge of the global economy in order to find growth wherever it occurs.

Team Overview

We believe deep industry expertise, broad investment knowledge, a highly collaborative decision-making process and individual accountability are a powerful combination. Since the inception of the team, we have been committed to building a team of growth investors that retains these attributes and is solely dedicated to our process and approach.

Portfolio Management



Jason White, CFA
Portfolio Manager (Lead)



James Hamel, CFA
Portfolio Manager



Matthew Kamm, CFA
Portfolio Manager



Craig Cepukenas, CFA
Portfolio Manager



Jay Warner, CFA
Portfolio Manager

Investment Results (%)

As of 31 December 2023	Average Annual Total Returns						Inception
	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	
Class I USD—Inception: 21 Aug 2017	10.15	20.83	20.83	-1.98	14.45	—	11.68
MSCI All Country World Index (USD)	11.03	22.20	22.20	5.75	11.72	—	8.96
Class I NOK (Hedged)—Inception: 03 Feb 2020	9.39	17.94	17.94	-4.15	—	—	5.23
MSCI All Country World Index (NOK)	5.97	25.98	25.98	11.94	—	—	11.26
Class I EUR—Inception: 02 Feb 2023	5.51	5.30	—	—	—	—	5.30
MSCI All Country World Index (EUR)	6.42	10.55	—	—	—	—	10.55

Annual Returns (%) Trailing 12 months ended 31 December

	2019	2020	2021	2022	2023
Class I USD	42.90	45.95	12.83	-30.92	20.83

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized.

Past performance does not predict future returns. Performance is NAV to NAV, including reinvestment of dividends and capital gains, if any, and is net of fees and expenses, excluding any subscription or redemption charges which may be levied. At the moment, the Fund does not intend to charge subscription or redemption fees. The Fund may be offered in different share classes, which are subject to different fees, expenses and inception dates (which may affect performance), have different minimum investment requirements and are entitled to different services. Funds are actively managed and are not managed to a benchmark index.

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in funds denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described on the last page, which should be read in conjunction with this material.

Performance commentary is provided in relation to the Fund's USD share class.



Investing Environment

The final quarter continued a trend we have witnessed throughout 2023, the gyration between recession fears and soft-landing optimism. Entering Q4, the market was comfortable that central banks had finished hiking but cautious about how long rates would remain at restrictive levels (i.e., higher for longer). However, a series of softer inflation prints in the US eased those fears, and investor expectations shifted toward a series of rate cuts in 2024. This view was compounded at the December Federal Open Market Committee meeting, where the latest Summary of Economic Projections suggested three cuts over 2024. Furthermore, Fed Chair Jerome Powell's messaging seemed to shift more dovish as he did not use the press conference to push back on the market's pricing in cuts next year. The 10-year Treasury yield started the quarter at 4.57%, reached a high of 4.99% on October 19 and then fell all the way to 3.88% by year end.

The shift in monetary policy expectations, combined with resilient economic data and better-than-expected corporate earnings results, led to a significant broad market rally in the quarter. US equities (measured by the Russell 1000® Index) delivered a 12.0% return, non-US developed markets (MSCI EAFE Index) delivered a local return of 5.0% and emerging markets (MSCI Emerging Markets Index) delivered a local return of 5.6%. The end of "higher for longer" rates fears boosted growth stocks, which delivered 14.2% (Russell 1000® Growth Index), but value stocks also delivered a respectable 9.5% (Russell 1000® Value Index). Small caps, which had struggled for most of the year, bounced back to deliver 14.0% (Russell 2000® Index).

Despite the grim outlook entering 2023, the MSCI AC World Index finished the year with a 22.2% gain as inflationary pressures faded while economic activity remained relatively unscathed. Perhaps one of the most significant surprises this year has been the US consumer, which has shown continued spending strength due to a healthy job market, rising wages and the benefit of long-term fixed rate debt. A resilient consumer has called into question how rate sensitive the economy is relative to history. With consumption making up about 70% of US economic activity, it is the foundation of economic strength.

Exhibit 1: Index Returns

	Q4 2023	2023
Russell 1000® Index	12.0%	26.5%
Russell 1000® Growth Index	14.2%	42.7%
Russell 1000® Value Index	9.5%	11.5%
Russell Midcap® Index	12.8%	17.2%
Russell Midcap® Growth Index	14.5%	25.9%
Russell Midcap® Value Index	12.1%	12.7%
Russell 2000® Index	14.0%	16.9%
Russell 2000® Growth Index	12.7%	18.7%
Russell 2000® Value Index	15.3%	14.6%
MSCI EAFE Index	5.0%	16.8%
MSCI AC World Small Cap Index	10.4%	16.1%
MSCI EM Index	5.6%	10.3%
MSCI ACWI	9.5%	22.2%
Brent Crude Oil	-19.0%	-6.2%
US Dollar Index	-4.6%	-2.1%

Source: Artisan Partners/FactSet/MSCI/Russell. As of 31 Dec 2023. **Past performance does not guarantee and is not a reliable indicator of future results.** An investment cannot be made directly in an index.

Performance Discussion

Our portfolio generated a positive absolute return in Q4 but underperformed the MSCI AC World Index. From a sector perspective, allocations benefited relative performance while security selection detracted. Looking at allocation impacts, the portfolio's overweight to information technology and lack of exposure to energy contributed to relative results. Negative security selection was driven by underperformance in information technology and health care. Within health care, shares of Argenx and Veeva sold off after delivering disappointing updates in Q4. We will discuss each of those later.

Within information technology, our portfolio delivered solid results in software, but several semiconductor holdings disclosed weakness due to cyclical end-market pressures. Our experience in this industry has taught us these cyclical corrections tend to be relatively short-lived (quarters rather than years), and we expect the secular trends driving growth for our businesses to easily overcome

macro pressures over a reasonable time frame. We remain patient. Underperformance within health care and information technology was partially offset by outperformance within industrials and consumer discretionary, where numerous holdings across home improvement (Trex), restaurants (Wingstop) and specialty retail (Five Below) performed well.

For the year, our portfolio generated strong returns that underperformed the MSCI AC World Index but meaningfully outperformed the MSCI AC World Small Mid Index.

From a sector perspective, security selection drove underperformance versus the MSCI AC World Index, most notably within information technology and industrials. This was partially offset, however, by outperformance within health care. From an allocation standpoint, the portfolio benefited from its overweight to information technology (the best performing sector in the index for the year), but this was partially offset by our overweight to health care (the index's third-worst performing sector, ahead of energy and utilities). As a strategy more focused on small- and mid-cap companies, market cap positioning relative to the MSCI AC World Index was a strong headwind in 2023; the Magnificent Seven group of stocks drove over 40% of the index's total return. By market cap, our portfolio's lack of exposure to companies >\$250 billion (versus 27% for the index) along with our sizable overweight to companies <\$25 billion (66% versus 22% for the index) hurt relative performance by more than 700bps.

This market cap impact was felt mostly within information technology. Our lack of exposure to NVIDIA, Microsoft and Apple was the main source of negative security selection, and it overshadowed multiple strong performances within semiconductors (despite declines late in the year) and software. We entered 2023 believing the valuations of our software holdings were attractive relative to their resilient subscription-based business models. At the same time, management teams were increasing their focus on margin expansion following the pandemic-era tech boom. While software industry revenue growth is being held back by macro pressures, our holdings are both gaining market share, and, as we expected, expanding margins due to a refocus on productivity.

While our overweight to health care was a large allocation headwind, it was our strongest area of security selection, as our companies leveraged to the growth in GLP-1 obesity therapies performed well. We are always interested in broader supply chain implications from big, new secular trends. In the case of new obesity therapies, we believe they will create major opportunities for certain biomanufacturing suppliers. These drugs are weekly, self-administered injections using "pen" devices common to insulin therapy. We believe the growth of these therapies represents an excellent opportunity for the companies that produce components of these pens, and we own two of them. West Pharmaceutical Services is a leading supplier of packaging components, such as rubber stoppers, seals and plungers, and Gerresheimer is a leading producer of specialty glass and plastic products.

Among our top contributors in Q4 were Advanced Micro Devices (AMD), Melrose Industries and Trex. Advanced Micro Devices was the top contributing stock for both Q4 and 2023, and it is a good example of our process. When we initiate a position, we aim to buy true small- or mid-cap securities with a market cap less than ~\$30 billion. However, we will let winners run if we continue to have high conviction in their ongoing profit cycle. We purchased AMD in July 2019 when it had a \$34 billion market cap, and it has grown to \$238 billion by the end of 2023. AMD's data center central processing units (CPUs) are used in cloud service provider (CSP) servers. In addition to the broad secular tailwind from cloud adoption, the company has a performance and pricing advantage over Intel, which we believe will enable it to continue capturing market share. However, stock price strength in Q4 (and throughout 2023) was due to growing excitement around the company's AI exposure and its MI300 GPU chip launch to compete against the dominant market leader, NVIDIA. Similar to its approach that won market share from Intel within the CPU market, AMD's GPU product aims to provide similar performance at a more attractive price. Using assumptions based on the total GPU market size, potential market share gains and product price points, our research indicates this could be a \$20 billion opportunity for AMD, which would nearly double its revenue. After the strong performance, we trimmed the position based on our valuation discipline.

Melrose is an engine component and airframe structure supplier for both commercial and defense aircraft. It operates in an oligopolistic industry, it is a supplier to all the world's high-volume aircraft manufacturers, and 70% of its revenues come from products that only it makes. After shareholders voted earlier this year to spin off the automotive division, it has become a focused aerospace company. We believe the company's engine business is entering a growth and profitability sweet spot, as an aging aircraft fleet should drive meaningful growth in high-margin aftermarket maintenance revenue. Shares rallied after the company reported 18% revenue growth and margins above expectations, driven by higher aftermarket demand and pricing. Given the thesis-affirming results, we added to the position.

Trex manufactures non-wood decking products. The company went through a period of underperformance in 2022 as rising mortgage rates curtailed demand for its outdoor products and inventory built up. However, as it became evident that these inventory headwinds were subsiding, we initiated a position in April of this year. Financial results have been strong as consumer awareness of composite decking's low to no maintenance features continues to grow, and the company has introduced lower priced options to appeal to a broader consumer income range. We believe growing market penetration can propel the company's growth for years, with additional upside potential from entering adjacent product categories.

Among our top detractors for Q4 were Argenx, ON Semiconductor and Veeva. Argenx is a commercial-stage biotechnology company with an approved first-in-class, and potentially best-in-class,

therapy (Vyvgart) for autoimmune diseases. The Vyvgart launch in myasthenia gravis continues to shine, with sales reaching north of \$1 billion ahead of schedule. And the company reported compelling phase 3 clinical trial data in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), which we expect to be Vyvgart's second blockbuster indication. But in Q4, trials for two additional indications surprisingly failed, marring an otherwise stellar year. While disappointing, we continue to have high confidence in the company. Vyvgart has multibillion-dollar sales potential just in its myasthenia gravis and CPID indications, and it is being studied in 11 additional diseases (with more on the drawing board). The company also has a second promising autoimmune disease drug in mid-stage clinical trials.

ON Semiconductor is a leading designer and manufacturer of chips for power management and image sensors. In particular, it is a leading producer of silicon carbide (SiC) chips that go into battery-electric vehicles (EVs). Shares fell after the company reported disappointing earnings results due to headwinds in its automotive segment. While overall auto demand weakness due to macroeconomic pressures was expected, we were disappointed that the multiyear take-or-pay contracts didn't protect it from short-term gyrations in customer demands. In light of that weakness, we realized inventories could drag on results into 2024, and we decided to trim our position while we wait for signs of resumed growth momentum in this end market.

Veeva Systems has the dominant customer relationship management platform for pharmaceutical sales and marketing organizations, and it is replicating that success with the rollout of numerous other modules focused on pharmaceutical R&D departments. The company reported earnings results that were in line with expectations; however, shares experienced weakness due to management's lowering its forward guidance as various factors—macroeconomic uncertainty and an ongoing squeeze in pre-commercial biotechnology investment—are leading customers to scrutinize their budgets and delay projects. We believe Veeva is a premier franchise whose growth can reaccelerate over time as its clinical software and data products reach mass adoption by the pharmaceutical industry. However, without a visible 2024 catalyst, we concluded that our position size was too large and trimmed it. With the company's balance sheet (overly) flush with cash, we would like to see share repurchases given the stock's depressed valuation. But this does not seem to be a board priority.

Portfolio Activity

We initiated new GardenSM positions in Quanta Services, Equifax and Brunello Cucinelli during the quarter. Quanta provides outsourced skilled labor for maintenance and construction services, primarily to utilities. We have followed the company for over a decade and have witnessed its shift from oil and gas to renewables. Energy transition (solar and wind farms, electric vehicles, etc.) requires investments in the US energy grid to support greater electrification. At the same time, climate change is increasing stress on the existing grid, forcing utilities to increase maintenance spending. Furthermore, Federal incentive programs, such as the Inflation Reduction Act and Bipartisan Infrastructure Act, should help fuel Quanta's long-term growth; as renewable energy

infrastructure comes online, they will require the company's expertise in transmission and distribution to connect to the grid. The stock sold off early in the quarter on concerns that higher interest rates would lead utility customers to pull back their renewables investments. However, based on our industry research, we think Quanta's key customers are well resourced and committed to meeting long-term electrification needs via infrastructure investment. We used the selloff as an opportunity to initiate a GardenSM position.

Equifax is the largest provider of income and employment in the US (workforce solutions) and one of the three large global credit bureaus. Within its credit business, we believe mortgage volumes likely troughed in 2023, driven by 30-year fixed mortgage rates reaching 20-year highs. Going forward, we expect either interest rates will fall or consumers will get used to a new normal. In either case, home purchase volume should recover. Meanwhile, its workforce solutions business has meaningful growth opportunities, including serving public sector clients seeking to verify public benefits eligibility and human resources departments running background checks on new employees. We expect steady growth in workforce solutions plus a multiyear recovery in mortgage-related revenues to drive significant margin expansion, enhanced by Equifax's large data and systems investments.

Brunello Cucinelli produces luxury clothing and accessories. The franchise is defined by its strong brand, and the company offers a defensive earnings profile due to its loyal and recurring ultra-high-net-worth customers. The company's products are 100% made in Italy with high-quality raw materials, have a high degree of artisanal craftsmanship and command high prices. We believe the company remains under-penetrated within several big luxury markets, such as China where it only generates ~10% of total sales versus 25%–30% for its peers. We believe Brunello Cucinelli is well positioned to deliver sustainable and defensive double-digit earnings growth for many years, given rising global brand recognition, increasing store penetration growth and gradual margin expansion.

We ended our investment campaigns in Metso, CNH Industrial and Davide Campari-Milano during the quarter. Metso is the leading provider of downstream mining equipment. Our thesis was driven by the company's new management team driving margin expansion and order growth within its minerals division. The division should be benefiting from a capital investment cycle in mining and increasing demand for copper mining solutions and equipment, as EVs and solar panels are increasingly adopted. However, financial results were disappointing over our holding period, and we decided to exit the position.

CNH Industrial is the second-largest global agricultural equipment company (primarily tractors and combines) with leading brands Case IH and New Holland. After a long period of relatively stagnant technological developments in the agricultural field, CNH is on a journey to meaningfully expand its technological offerings in areas such as precision agriculture and autonomous technology. Our research indicates the world's fleet of agricultural equipment is as old as it has been in 40 years. We believe there is pent-up demand at a time of new technological innovation, which sets up CNH for a

long-term secular growth opportunity. While we maintain conviction in CNH over the long term, we are cognizant of the possibility that agriculture market trends have peaked in the short term. Combining that with signs of economic pressure and the potential for tighter lending standards, we decided to exit the position in favor of more attractive near-term ideas.

Davide Campari-Milano produces and distributes alcoholic and non-alcoholic beverages worldwide. Our thesis was driven by our views that Campari was a durable consumer franchise, it owned great assets in a structurally attractive industry, and its management team had a strong track record of overseeing organic growth and making accretive mergers and acquisitions. The CEO recently announced his retirement, which, combined with an elevated valuation, led us to exit the position.

Along with Melrose, notable adds in the quarter included Exact Sciences and Hubbell. Exact Sciences is a leading provider of diagnostic testing and a maker of the noninvasive colorectal cancer screening test Cologuard®. We believe management's targets are conservative, in part due to a meaningful expansion in the addressable market for Cologuard® since the United States Preventive Services Task Force in 2021 lowered the recommended age at which people should be screened for colorectal cancer (from 50 to 45 years old). Our research indicates this expands the company's addressable market by another ~18 million unscreened individuals. We also believe meaningful long-term opportunities exist as the company develops additional high-value cancer tests. Given this growth outlook and a recent transition to profitability, we added to our position and moved it to the top of the GardenSM.

Hubbell manufactures and sells electrical products for a wide range of utility, commercial, residential and industrial applications. The US electrical grid needs substantial investment to avoid outages and support the future proliferation of green energy installations. As a leading supplier of transmission and distribution components to utilities, we believe Hubbell is well positioned. Shares experienced weakness after the company reported earnings results that lagged consensus, but utility segment growth remained strong, and management provided optimistic forward guidance for 2024. The company also announced the acquisition of Systems Controls, which we believe allows Hubbell to offer differentiated products within its utility business along with cross-selling synergies. We have moved the position into the top of the GardenSM based on our view that its valuation is reasonable, its profit cycle momentum is supported by the grid modernization trend, and its recent acquisition will be accretive to earnings.

Along with AMD, ON Semiconductor and Veeva, notable trims in the quarter included HubSpot. Like many software companies, HubSpot's revenue growth has slowed from the torrid pace seen in recent years. While this slowing weighed heavily on the stock in 2022, financial results through 2023 displayed stabilization across many important metrics, including revenue, customer adds and earnings. But the highlight was operating margins, where management forecasted a long-term target of 20%–25% versus 10% in 2022. The company is taking advantage of less frenetic demand conditions to improve its profitability after several years of

heavy investment. We are also encouraged by the company's efforts to leverage AI advances to help internally (e.g., more efficient software development) and externally (e.g., new chat-based apps to help customers extract more value out of its products). After a period of strong performance, we trimmed the position based on our valuation discipline.

Stewardship Update

We view robust corporate governance practices as essential to the mitigation of unwarranted risk taking and the fulfillment of sustainable business strategies. However, establishing the parameters of good governance in practice can become a check-the-box exercise that is overly dependent upon board structure and governance statistics.

In 2023, we began incorporating a more structured and detailed assessment of board composition, skills matrices and effectiveness reviews into our engagement activities with portfolio companies. To get beyond the metrics, our conversations focus on the process a board employs to assess the alignment of director skillsets with long-term strategic objectives—specifically, how it determines both when and which new skills or background experiences will be required to ensure the board is able to oversee the next phase of the company's growth.

We are also keenly interested in understanding how a board assesses its own culture and organizational effectiveness as a strategic oversight body. While companies often highlight annual evaluations in their governance documents or proxy filings, disclosure around the underlying components of the process is typically limited. In our engagements with portfolio companies, we endeavor to gain clarity and to better understand the approach and comprehensiveness of the evaluation process, as well as how a board responds to the concerns raised by its directors.

The cumulative set of responses we have received over the last year has greatly enhanced our ability to effectively assess the quality of board-level leadership, strategic oversight and organizational alignment. We have become more adept at discerning whether boards are equipped to deploy thoughtful and robust governance practices that align with a company's long-term strategic objectives.

Perspective

The market continues to be dominated by macroeconomic narratives. The soft versus hard landing debate (and what that means for the interest rate cycle) drove market trading patterns for much of 2023. As we entered Q4, investors were concerned about a higher-for-longer interest rate stance from the Fed, but those fears quickly dissipated as falling inflation and resilient economic data suggested the Fed may be orchestrating a soft landing. This led to a major fall in yields and a rally in equities, which may have pulled forward some expected market returns from 2024.

It is reasonable to assume macro-driven volatility will continue this year, especially given the looming US presidential election. However, our investment process points us toward high-quality

franchises with growth drivers that extend beyond short-term market cycles. These powerful trends were clearly on display within the portfolio's information technology holdings in 2023. Specifically, productivity-enhancing software applications continue to see solid growth (albeit at a less torrid pace than during the pandemic) as businesses transform their operations. While software developers are rapidly exploring the power of new generative AI tools, we believe the opportunity for software vendors to expand the power of their solutions via integrated AI is in the early innings. Within semiconductors, despite the cyclical headwinds late in the year, we have high confidence that the secular drivers—data centers, AI, vehicle electrification and industrial automation—will drive solid growth over medium- and long-term horizons.

Health care was an area where our confidence in innovation and secular trends did not translate into strong stock performance in 2023. We think there are several reasons why the sector has been out of favor, including concerns about early-stage biotechnology funding in a higher rate environment, the unwinding of COVID-19 related spending on vaccines, testing and supplies, reduced spending by China life sciences companies and fears over US drug price regulation. However, along with the broader industry headwinds, we also experienced some idiosyncratic disappointments in our health care portfolio, including Argenx and Ascendis.

Any time we experience noticeable underperformance in an economic sector, we work hard to retest our assumptions and challenge ourselves to be open-minded to the possibility that our investment thesis is off target. In some cases, this has led us to reduce positions where new evidence suggested the profit cycle dynamics have deteriorated (Veeva). But, in most cases, we remain very optimistic about the mid- and long-term profit growth potential of our key health care holdings. For example, we opportunistically added to Exact Sciences after an earnings-related selloff in Q4, maintained our position in Ascendis following the FDA's request for additional manufacturing data in Q2 and added to our position in West Pharmaceuticals toward the end of 2023 on the belief that the COVID-19 vaccine overhang would fade. These actions began to bear fruit as the year went on, and we believe our patience with these stocks, along with Argenx, Shockwave and iRhythm, leave our portfolio's health care exposure well positioned entering 2024.

While information technology and health care are the two largest sector exposures in the portfolio, and our conviction in these holdings remains high, we have always said we look for growth wherever it's occurring. In 2023, we were very encouraged by our team's ability to find a number of interesting GardenSM investments within the Internet, consumer and industrial sectors. Some of these recent opportunities have been driven by emerging secular trends like renewable energy within industrials (Quanta Services, Hubbell), while others have been driven by taking advantage of depressed valuations in consumer Internet companies coming out of the growth stock selloff in 2022. We have also uncovered idiosyncratic opportunities in a diverse set of high-quality franchises—businesses such as Melrose Industries, Pool Corp, Adidas, Trex and Live Nation—that we believe are early in their profit cycles. Overall,

we believe we enter 2024 with attractive opportunities across the sector landscape.

Much uncertainty about the economy's direction remains, but we continue to follow our process to find high-quality franchises with positive profit cycle outlooks. With valuations for growth equities still at reasonable levels, we believe these investments can yield attractive returns for longer term investors across most macroeconomic scenarios.

ARTISAN CANVAS

Timely insights and updates from our investment teams and firm leadership

Visit www.artisancanvas.com

For more information: Visit www.artisanpartners.com

International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging and less developed markets, including frontier markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. The costs associated with this fund will impact your return over time. Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in funds denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described in the Fund Documents.

This is a marketing communication. Further fund details, including risks, fees and expenses, and other information, such as ESG practices, are set out in the current Prospectus, Supplements, Key Information Documents (KIDs) and other documentation (collectively, the Fund Documents), which can be obtained by calling +44 (0) 207 766 7130 or visiting www.apgfunds-docs.com. Please refer to the Fund Documents and consider all of a fund's characteristics before making any final investment decisions.

This summary represents the views of the portfolio managers as of 31 Dec 2023. Those views may change, and the Fund disclaims any obligation to advise investors of such changes. Portfolio holdings are displayed in the context of marketing the fund shares and not the marketing of underlying portfolio securities. For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The holdings mentioned above comprise the following percentages of the Fund's total net assets as of 31 Dec 2023: Veeva Systems Inc 3.8%, Melrose Industries PLC 3.2%, Gerresheimer AG 3.1%, Argenx SE 2.9%, Advanced Micro Devices Inc 2.3%, ON Semiconductor Corp 2.3%, West Pharmaceutical Services Inc 2.2%, Ascendis Pharma A/S 2.0%, adidas AG 1.9%, Trex Co Inc 1.9%, HubSpot Inc 1.6%, iRhythm Technologies Inc 1.5%, Quanta Services Inc 1.3%, Five Below Inc 1.3%, Exact Sciences Corp 1.3%, Hubbell Inc 1.1%, Shockwave Medical Inc 1.1%, Pool Corp 1.1%, Live Nation Entertainment Inc 1.0%, Wingstop Inc 0.8%, Equifax Inc 0.7%, Brunello Cucinelli SpA 0.7%. Securities named in the Commentary, but not listed here are not held in the Fund as of the date of this report. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities.

ESG assessments represent one of many pieces of research available and the degree to which it impacts holdings may vary based on manager discretion.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

MSCI All Country World Index measures the performance of developed and emerging markets. Russell 1000® Index measures the performance of roughly 1,000 US large-cap companies. Russell 1000® Growth Index measures the performance of US large-cap companies with higher price/book ratios and forecasted growth values. Russell 1000® Value Index measures the performance of US large-cap companies with lower price/book ratios and forecasted growth values. Russell 2000® Index measures the performance of roughly 2,000 US small-cap companies. Russell Midcap® Index measures the performance of roughly 800 US mid-cap companies. Russell Midcap® Growth Index measures the performance of US mid-cap companies with higher price/book ratios and forecasted growth values. Russell Midcap® Value Index measures the performance of US mid-cap companies with lower price/book ratios and forecasted growth values. Russell 2000® Growth Index measures the performance of US small-cap companies with higher price/book ratios and forecasted growth values. Russell 2000® Value Index measures the performance of US small-cap companies with lower price/book ratios and forecasted growth values. MSCI EAFE Index measures the performance of developed markets, excluding the US and Canada. MSCI All Country World Small Cap Index measures the performance of small-cap companies in developed and emerging markets. MSCI Emerging Markets Index measures the performance of emerging markets. MSCI All Country World Small/Mid Cap Index measures the performance of small- and mid-cap companies in developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

Portfolio statistics are obtained from various data sources and intended to provide a general view of the portfolio, or Index, at a point in time. Artisan Partners excludes outliers when calculating portfolio characteristics and may use data from a related security to calculate statistics if information is unavailable for a particular security. **Private Market Value** is an estimate of the value of a company if divisions were each independent and established their own market stock prices. **Magnificent Seven (M7)** is a term used to describe large US companies: Apple, Amazon, Alphabet, Tesla, NVIDIA, Microsoft and Meta. **Operating Margin** is a measure of profitability equal to operating income divided by revenue.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

This material is provided for informational purposes without regard to your particular investment needs and shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein. Artisan Partners is not registered, authorised or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorised or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

APLP is the investment manager of Artisan Partners Global Funds Plc (APGF), an umbrella type open-ended investment company with variable capital having segregated liability between its sub-funds, incorporated with limited liability and authorized in Ireland by the Central Bank of Ireland as an Undertaking for Collective Investments in Transferable Securities (UCITS) under registration number 485593. APUK and AP Europe are the distributors for APGF. This material is not intended for use within the US or with any US persons. The Fund shares described herein are not and will not be, registered under the US Securities Act of 1933 and may not be sold to or for the benefit of any US person.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia. No cooling-off regime applies to an acquisition of the interests in any funds managed by Artisan Partners described herein. **Austria:** The shares described herein and in each Fund's prospectus and the related documents have not and may not be offered or sold, directly or indirectly, to the public in the Republic of Austria. Each Fund's prospectus has not been and will not be submitted to the Oesterreichische Kontrollbank Aktiengesellschaft and has not been prepared in accordance with the Austrian Capital Markets Act (Kapitalmarktgesetz) or the Austrian Investment Funds Act (Investmentfondsgesetz). Each is therefore not a prospectus pursuant to the Capital Markets Act or the Investment Funds Act. **Brazil:** Shares in the Fund may not be offered or sold to the public in Brazil. Accordingly, the Fund shares have not been nor will be registered with the Brazilian Securities Commission - CVM nor have they been submitted to the foregoing agency for approval. Documents relating to the Fund shares, as well as the information contained therein, may not be supplied to the public in Brazil, as the offering is not a public offering of securities in Brazil, nor used in connection with any offer for subscription or sale of securities to the public in Brazil. **Canada:** This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conducts activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws. Investment in the securities of Funds managed and distributed by APLP and/or Artisan Partners Distributors LLC may only be made by eligible private placement purchasers that qualify as "accredited investors" and "permitted clients" under applicable Canadian securities laws and pursuant to Canadian private placement offering documents, which are available upon request. This material is not, and under no circumstances should it be construed as, a private placement offering document, advertisement or public offering of securities in Canada. No securities commission or similar authority in Canada has reviewed this material or in any way passed upon the merits of any securities referenced herein and any representation to the contrary is an offence. **Chile:** Esta oferta privada se acoge a las disposiciones de la norma de carácter general n° 336 de la superintendencia de valores y seguros, hoy comisión para el mercado financiero. Esta oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva la comisión para el mercado financiero, por lo que tales valores no están sujetos a la fiscalización de ésta; por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en Chile información pública respecto de los valores sobre los que versa esta oferta; estos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores correspondiente. **Bailiwick of Guernsey:** This material is only being, and may only be, made available in or from within the Bailiwick of Guernsey to persons licensed under the Protection of Investors Law, 1987, the Banking Supervision Law, 1994, the Regulation of Fiduciaries, Administration Businesses and Company Directors, etc. Law, 2000 or the Insurance Managers and Insurance Intermediaries Law, 2002. **Hong Kong:** This material has not been registered by the Registrar of Companies in Hong Kong. The Fund is a collective investment scheme as defined in the Securities and Futures Ordinance of Hong Kong (the "Ordinance") but has not been authorised by the Securities and Futures Commission pursuant to the Ordinance. Accordingly, the shares may only be offered or sold in Hong Kong to persons who are "professional investors" as defined in the Ordinance and any rules made under the Ordinance or in circumstances which are permitted under the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong and the Ordinance. In addition, this material may not be issued or possessed for the purposes of issue, whether in Hong Kong or elsewhere, and the shares may not be disposed of to any person unless such person is outside Hong Kong, such person is a "professional investor" as defined in the Ordinance and any rules made under the Ordinance or as otherwise may be permitted by the Ordinance. **Israel:** This material has not been approved by the Israel Securities Authority and will only be distributed to Israeli residents in a manner that will not constitute "an offer to the public" under sections 15 and 15a of the Israel Securities Law, 5728-1968 (the Securities Law) or section 25 of the Joint Investment Trusts Law, 5754-1994, as applicable. The Fund is being offered to a limited number of investors and/or those categories of investors listed in the First Addendum to the Securities Law (Sophisticated Investors). This material may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Any offeree who purchases shares of a Fund is purchasing such Fund for its own benefit and account and not with the aim or intention of distributing or offering such Fund to other parties (other than, in the case of an offeree which is a Sophisticated Investor by virtue of it being a banking corporation, portfolio manager or member of the Tel-Aviv Stock Exchange, as defined in the Addendum, where such offeree is purchasing Fund for another party which is a Sophisticated Investor). Nothing in this material should be considered investment advice or investment marketing as defined in the Regulation of Investment Counselling, Investment Marketing and Portfolio Management Law, 5755-1995 (the Investment Advice Law). Investors are encouraged to seek competent investment counselling from a locally licensed investment counsel prior to making the investment. Artisan Partners does not hold a licence under the Investment Advice Law, nor does it carry the insurance as required of a licensee thereunder. **Jersey:** This material relates to a private placement and does not constitute an offer to the public in Jersey to subscribe for the Fund offered hereby. No regulatory approval has been sought to the offer in Jersey and it must be distinctly understood that the Jersey Financial Services Commission does not accept any responsibility for the financial soundness of or any representations made in connection with the Fund. The offer of shares is personal to the person to whom this material is being delivered by or on behalf of the Fund, and a subscription for the shares will only be accepted from such person. The material may not be reproduced or used for any other purpose. **Mexico:** The Fund has not been and will not be registered with the National Registry of Securities, maintained by the Mexican National Banking and Securities Commission and, as a result, may not be offered or sold publicly in Mexico. The Fund and any underwriter or purchaser may offer and sell the Fund in Mexico on a private placement basis to Institutional and Accredited Investors pursuant to Article 8 of the Mexican Securities Market Law. **New Zealand:** This material is not a product disclosure statement for the purposes of the Financial Markets Conduct Act 2013 (the FMCA) and does not contain all the information typically included in such offering documentation. This offer of shares in the Fund does not constitute "regulated offer" for the purposes of the FMCA and, accordingly, there is neither a product disclosure statement nor a register entry available in respect of the offer. Shares in the Fund may only be offered in New Zealand in accordance with the FMCA and the Financial Markets Conduct Regulations 2014. **Oman:** The information contained in this material neither constitutes a public offer of securities in the Sultanate of Oman as contemplated by the Commercial Companies Law of Oman (Royal Decree 4/74) or the Capital Market Law of Oman (Royal Decree 80/98), nor does it constitute an offer to sell, or the solicitation of any offer to buy Non-Omani securities in the Sultanate of Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market Law (issued by Decision No.1/2009). Additionally, this private placement memorandum is not intended to lead to the conclusion of any contract of whatsoever nature within the territory of the Sultanate of Oman. **Peru:** The Fund has not been registered before the Superintendencia del Mercado de Valores (SMV) and is therefore being placed by means of a private offer. SMV has not reviewed the information provided to the investor. This material is only for the exclusive use of institutional investors in Peru and is not for public distribution. **Qatar:** The Funds are only being offered to a limited number of investors who are willing and able to conduct an independent investigation of the risks involved in an investment in such Funds. This material does not constitute an offer to the public and is for the use only of the named addressee and should not be given or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof). The Funds have not been and will not be registered with the Qatar Central Bank or under any laws of the State of Qatar. No transaction will be concluded in your jurisdiction and any inquiries regarding the Funds should be made to Artisan Partners. **Singapore:** APGF is currently entered into the Monetary Authority of Singapore's (MAS) List of Restricted Schemes. This document has not been registered as a prospectus with the MAS. Accordingly, this and any other material in connection with the offer or sale, or invitation for subscription or purchase, of shares of the sub-funds of APGF may not be circulated or distributed, nor may shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (SFA) or (ii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. **Switzerland:** The Prospectus, the Key Investor Information Document(s), the Articles of Association of the Company and the latest annual and semi-annual reports can be obtained free of charge from the representative in Switzerland, State Street Bank GmbH, Munich, Zurich Branch, Beethovenstrasse 19, CH-8002 Zurich, Switzerland. The place of performance and jurisdiction is at the registered office of State Street Bank GmbH. State Street Bank GmbH is also the paying agent of the Company.

© 2024 Artisan Partners. All rights reserved.

